Next-generation sequencing for measuring minimal residual disease in AML

Roland B Walter^{1

2

3}, Frederick R Appelbaum^{4

5}

Affiliations

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
² Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
³ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁴ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. fappelba@fredhutch.org.
⁵ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. fappelba@fredhutch.org.

Comment

Roland B Walter et al. Nat Rev Clin Oncol. 2018 Aug.

. 2018 Aug;15(8):473-474.

doi: 10.1038/s41571-018-0040-0.

Roland B Walter^{1

2

3}, Frederick R Appelbaum^{4

5}

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
² Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
³ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁴ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. fappelba@fredhutch.org.
⁵ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. fappelba@fredhutch.org.

No abstract available

Comment on

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM. Jongen-Lavrencic M, et al. N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863. N Engl J Med. 2018. PMID: 29601269